๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Non-squamous Metastatic Non-Small-Cell Lung Carcinoma

A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC NCT06754644Phase 31 site๐Ÿ“ Jinan Qilu Pharmaceutical Co., Ltd. ยท Tests: QL2107, Pemetrexed, Carboplatin, Keytrudaยฎ GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors NCT04977453Phase 1, Phase 213 sites๐Ÿ“ New York๐Ÿ“ New York๐Ÿ“ Huntersville GI Innovation, Inc. ยท Tests: GI-101, Pembrolizumab (KEYTRUDAยฎ), Lenvatinib, GI-101A A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies NCT05473156Phase 1, Phase 21 site๐Ÿ“ Taipei AP Biosciences Inc. ยท Tests: AP203, AP203 Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study NCT07405086Phase 41 site๐Ÿ“ Portland OHSU Knight Cancer Institute ยท Tests: Biospecimen Collection, Immune Checkpoint Inhibitor Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors NCT04777994Phase 130 sites๐Ÿ“ Tucson๐Ÿ“ New Haven๐Ÿ“ Baltimore Calico Life Sciences LLC ยท Tests: ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Deatโ€ฆ Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations NCT06772623Phase 1, Phase 2126 sites๐Ÿ“ Phoenix๐Ÿ“ Fullerton๐Ÿ“ Oxnard AbbVie ยท Tests: Telisotuzumab Adizutecan, Budigalimab, Pembrolizumab, Pembrolizumab, Carboplatin A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors NCT07277413Phase 123 sites๐Ÿ“ Goodyear๐Ÿ“ Phoenix๐Ÿ“ Duarte IDEAYA Biosciences ยท Tests: IDE892, IDE397 A Study of IDP-001 in Advanced or Metastatic Solid Tumors NCT07602842Phase 1, Phase 26 sites๐Ÿ“ Los Angeles๐Ÿ“ Sarasota๐Ÿ“ Indianapolis InduPro, Inc. ยท Tests: IDP-001 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors NCT06305962EARLY Phase 15 sites๐Ÿ“ Kingswood๐Ÿ“ Wollongong๐Ÿ“ Southport Radiopharm Theranostics, Ltd ยท Tests: 177Lu-RAD204 Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations NCT07336732Phase 21 site๐Ÿ“ Guangzhou Avistone Biotechnology Co., Ltd. ยท Tests: PLB1004 Effects of Infusion Timing on Treatment Response in Solid Tumors NCT07630168Phase 21 site๐Ÿ“ Chapel Hill UNC Lineberger Comprehensive Cancer Center ยท Tests: PD-1/PD-L1 inhibitor monotherapy - 4 cycles before 12:00PM, PD-1/PD-L1 inhibitor monotherapy - 4 cycles after 3 PM, PD-โ€ฆ NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations NCT06494540n/a30 sites๐Ÿ“ Bad Homburg๐Ÿ“ Berlin๐Ÿ“ Bremen AstraZeneca A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer NCT07155187Phase 2, Phase 3117 sites๐Ÿ“ Springdale๐Ÿ“ Duarte๐Ÿ“ Irvine AbbVie ยท Tests: Telisotuzumab Adizutecan, Standard of Care, Osimertinib Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors NCT06171750Phase 15 sites๐Ÿ“ Bethesda๐Ÿ“ Boston๐Ÿ“ Portland Ankyra Therapeutics, Inc ยท Tests: tolododekin alfa, Cemiplimab A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC NCT07264816Phase 21 site๐Ÿ“ Wuhan Sichuan Baili Pharmaceutical Co., Ltd. ยท Tests: BL-M07D1, Pembrolizumab A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types NCT07503808Phase 115 sites๐Ÿ“ Denver๐Ÿ“ Sarasota๐Ÿ“ Detroit IDEAYA Biosciences ยท Tests: IDE034 JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation NCT06416410Phase 337 sites๐Ÿ“ Hefei๐Ÿ“ Beijing๐Ÿ“ Beijing Allist Pharmaceuticals, Inc. ยท Tests: JAB-21822, Tislelizumab, JAB-3312, Pemetrexed, Carboplatin A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) NCT06692738Phase 3328 sites๐Ÿ“ Tucson๐Ÿ“ Springdale๐Ÿ“ Anaheim AstraZeneca ยท Tests: Rilvegostomig, Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors NCT07229313Phase 17 sites๐Ÿ“ Santa Monica๐Ÿ“ New Have๐Ÿ“ Camperdown Kivu Bioscience Inc. ยท Tests: KIVU-107 Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer NCT07416994Phase 32 sites๐Ÿ“ Shanghai๐Ÿ“ Hangzhou MediLink Therapeutics (Suzhou) Co., Ltd. ยท Tests: YL202, Docetaxel Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers NCT00900419n/a1 site๐Ÿ“ Aurora University of Colorado, Denver ยท Tests: immunohistochemistry staining method, laboratory biomarker analysis, sputum cytology, biopsy A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies NCT07613723Phase 12 sites๐Ÿ“ London๐Ÿ“ Manchester Zelluna Immunotherapy AS ยท Tests: ZI-MA4-1 (TCR-NK cells), Cyclophosphamide, Fludarabine A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC NCT06908304Phase 315 sites๐Ÿ“ Poznan๐Ÿ“ Craiova๐Ÿ“ Timiศ™oara Maia Biotechnology ยท Tests: 6-Thio-2'-Deoxyguanosine, Cemiplimab, Docetaxel, Vinorelbine, Gemcitabine alone A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) NCT06875310Phase 3351 sites๐Ÿ“ Birmingham๐Ÿ“ Springdale๐Ÿ“ Fullerton Mirati Therapeutics Inc. ยท Tests: Adagrasib, Pembrolizumab, Carboplatin, Pemetrexed, Placebo A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors NCT05914116Phase 1, Phase 2107 sites๐Ÿ“ Tucson๐Ÿ“ Los Angeles๐Ÿ“ Los Angeles DualityBio Inc. ยท Tests: DB-1311, Lopinavir and Ritonavir Tablets, itraconazole, Enzalutamide, Abiraterone A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer NCT07227168Phase 19 sites๐Ÿ“ San Diego๐Ÿ“ Denver๐Ÿ“ Washington D.C. Sutro Biopharma, Inc. ยท Tests: STRO-004, Pembrolizumab A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal Metastases NCT06901817Phase 21 site๐Ÿ“ Shanghai Shanghai Cancer Hospital, China ยท Tests: Intraventricular Pemetrexed, Intraventricular Nivolumab, Intraventricular Dexamethasone Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer NCT06899126Phase 3246 sites๐Ÿ“ Anchorage๐Ÿ“ Fountain Valley๐Ÿ“ Los Angeles Daiichi Sankyo ยท Tests: Trastuzumab Deruxtecan, pembrolizumab, Pemetrexed, Platinum Chemotherapy A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors NCT05592626Phase 1, Phase 219 sites๐Ÿ“ Sacramento๐Ÿ“ Celebration๐Ÿ“ Miami Marengo Therapeutics, Inc. ยท Tests: STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere) Study of XB010 in Subjects With Solid Tumors NCT06545331Phase 120 sites๐Ÿ“ Irvine๐Ÿ“ Los Angeles๐Ÿ“ Washington D.C. Exelixis ยท Tests: XB010, Pembrolizumab
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy